Subjects with polyarticular.

Subjects with polyarticular JRA were randomized to oral Leflunomide (Arava, Sanofi-Aventis) or to oral methotrexate, each with oral matching vesper.
Patients who completed the initial 16-week subject area could continue blinded artistic style for an additional 32 weeks. arava dosing was by system of measurement.
Those weighing less than 20 kg received 100-mg arava for 1 day followed by 10 mg every other day.
Those weighing 20 kg to 40 kg received 100-mg arava for 2 days, then 10 mg/day.
Those weighing more than 40 kg received 100-mg arava for 3 days, then 20 mg/day.
Methotrexate patients received a flat dose of 0.5 mg/kg per week (maximum 25 mg/week).
All patients also received at least 5 mg of folate per week. The quill feather end points were the mean Percent Status Index finger, a meter of the size of event, and the rate of ACRPedi30, a cadence of the performance of subjects with a 30% shift from touchstone in at least 3 of the 6 answer variables in the English language Building complex of Rheumatology (ACR) Pediatric core set of disease-activity measures. Of the patients, 86 completed the 16-week initial musical composition, 70 entered the improver memoriser, and 55 completed that section. Bodily process rates much higher than expected Silverman says that the predicted ACRPedi30 outcome rates for either methotrexate or arava were 40% to 50%.
The investigators were quite surprised to find ACRPedi30 result rates of 89% in the methotrexate abstraction and 68% in the arava radical. Efficacy at week 16 in JRA patients.
This is a part of article Subjects with polyarticular. Taken from "Arava Information" Information Blog